Physician profile
Mitchell Ryan Manway
NPI 1083024921
$5,717.39
in general payments reported to CMS, 2019-2025
29 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 82% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $59.86 · 2021: $86.26 · 2022: $810 · 2023: $990 · 2024: $1,112 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.12 |
| Education | $167.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,561.39 | 2019-2025 | |
| Genzyme Corporation | $567.78 | 2019-2025 | |
| Janssen Biotech, INC. | $527.36 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Incyte Corporation | $473.44 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $460.30 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $326.00 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $318.10 | 2022-2025 | Sotyktu |
| Pfizer INC. | $297.22 | 2019-2025 | |
| Galderma Laboratories, L.P. | $146.82 | 2019-2025 | Nemluvio |
| Kyowa Kirin, INC. | $132.07 | 2024-2025 | Poteligeo |
| Verrica Pharmaceuticals INC. | $115.98 | 2024 | Ycanth |
| Ucb, INC. | $103.37 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $103.34 | 2019-2025 | Anzupgo |
| Sun Pharmaceutical Industries INC. | $99.26 | 2019-2025 | Ilumya |
| Arcutis Biotherapeutics, INC. | $66.51 | 2024-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $58.64 | 2023-2025 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.04 | 2023-2025 | Spevigo |
| Organon LLC | $50.48 | 2025 | Vtama |
| Amgen INC. | $49.17 | 2019-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $46.06 | 2023-2024 | Vtama |
| Organogenesis INC. | $24.88 | 2025 | Puraply Wound Matrix |
| Springworks Therapeutics, INC. | $20.74 | 2025 | Gomekli |
| Celltrion USA INC. | $20.47 | 2024 | Vegzelma |
| Surgenex LLC | $18.28 | 2025 | Surmatrix, Pellograft, Renograft |
| Pierre Fabre Pharmaceuticals, INC. | $18.17 | 2019 | |
| Almirall LLC | $17.04 | 2025 | Klisyri |
| Lilly USA, LLC | $15.10 | 2025 | Taltz, Ebglyss |
| Journey Medical Corporation | $14.39 | 2025 | |
| Biowound Solutions, INC. | $6.99 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Manway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.